Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

STRATTERA 25 MG CAPSULE

Atomoxetine hydrochloride
$12.5675per EA

Strength

25 mg/1

Manufacturer

Eli Lilly and Company

NDC

00002322830

Classification

Brand

Dosage Form

CAPSULE

Route

ORAL

Last Updated

7/23/2025

Active Ingredients

ATOMOXETINE HYDROCHLORIDE

Approval Type

New Drug (NDA)

FDA Application

NDA021411

On Market Since

11/26/2002

Pharmacological Classes

Norepinephrine Reuptake Inhibitor
Norepinephrine Uptake Inhibitors

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

-0.3%

3Y

+0.0%

5Y

-0.7%

All

+90.4%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

CONTRAVE ER 8-90 MG TABLET
Brand
51267089099•Nalpropion Pharmaceuticals LLC
$4.9810
per EA
WELLBUTRIN SR 100 MG TABLET
Brand
00173094755•GlaxoSmithKline LLC
$7.0305
per EA
DRIZALMA SPRINKLE DR 60 MG CAP
Brand
47335061930•Sun Pharmaceutical Industries Inc.
$7.1571
per EA
DRIZALMA SPRINKLE DR 40 MG CAP
Brand
47335061830•Sun Pharmaceutical Industries Inc.
$7.1607
per EA
DRIZALMA SPRINKLE DR 20 MG CAP
Brand
47335061630•Sun Pharmaceutical Industries Inc.
$7.1719
per EA
DRIZALMA SPRINKLE DR 30 MG CAP
Brand
47335061730•Sun Pharmaceutical Industries Inc.
$7.2186
per EA
WELLBUTRIN SR 150 MG TABLET
Brand
00173013555•GlaxoSmithKline LLC
$7.5104
per EA
CYMBALTA 20 MG CAPSULE
Brand
00002323560•Eli Lilly and Company
$7.9836
per EA
SAVELLA 50 MG TABLET
Brand
00456155060•Allergan, Inc.
$8.1588
per EA
SAVELLA 12.5 MG TABLET
Brand
00456151260•Allergan, Inc.
$8.1597
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy